The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | MM trial highlights from ASCO 2018
Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, gives an overview of his top 5 abstract presentations at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. These include: the CRB-401 study (NCT02658929) showing positive results for anti-BCMA CAR T-cell agent idecabtagene vicleucel (formerly bb2121); ARROW (NCT02412878), which showed that once-weekly carfilzomib was as effective and well-tolerated as a twice-weekly dosage; COLUMBA (NCT03277105), which demonstrated subcutaneous daratumumab was safe and effective; OPTIMISMM (NCT01734928), which showed that a triplet therapy of pomalidomide, bortezomib and dexamethasone was well tolerated and more effective than bortezomib/dexamethasone alone; and SWOG-S1304 (NCT01903811), which showed no significant PFS or OS difference between low- and high-dose carfilzomib.
